The Endocrine Outlook: Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists

October 9, 2020

This episode of the Endocrine Outlook podcast features a discussion around the cardiorenal benefits of SGLT2 inhibitors and GLP-1 receptor agonists.

In this episode of the Endocrine Outlook, listeners will hear a conversation with Muthiah Vaduganathan, MD, MPH, a cardiologist at Brigham and Women’s hospital. Vaduganathan was also a member of the writing committee for a recent AHA scientific statement regarding the cardiorenal protective benefits of SGLT2 inhibitors and GLP-1 receptor agonists.

In the interview, Vaduganathan offers insight into the writing process and his perspective on how the most recent trials for these agents have added to our understanding of the classes.